Foster L B Co
Source
From SEC EDGAR
149 releases originally issued via SEC EDGAR. The issuing organizations are responsible for their content.
Madison Square Garden Entertainment Corp.
MADISON SQUARE GARDEN ENTERTAINMENT CORP. REPORTS
FISCAL 2027 FIRST QUARTER RESULTS
Vishay Intertechnology Inc
Vishay Intertechnology Reports Third Quarter 2026 Results
Trinity Capital Inc.
Trinity Capital Reports Third Quarter 2026 Financial Results
Return on Average Equity climbs to 15.5% in Q3
XPEL, Inc.
Ex. 99.1
XPEL Reports Revenue of $137.8 million; Revenue Growth of 9.9% in Third Quarter 2026
MoonLake Immunotherapeutics
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
•Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with…
Lifecore Biomedical, Inc. \De\
Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update
-- Multiple New Business Wins Continue to Strengthen Growing Pipeline --
Southwest Gas Holdings, Inc.
Southwest Gas Holdings, Inc. Reports Third Quarter 2026 Financial Results,
Reaffirms Full-Year 2026 Guidance
American Financial Group Inc
American Financial Group, Inc. Announces Third Quarter Results and Declares Special Dividend
CS Disco, Inc.
DISCO Announces Third Quarter 2026 Financial Results
Total Revenue of $45.3 Million, A Year over Year Increase of 11%, or 15% when Excluding the Contingent Matter in Q3 2025
SharkNinja, Inc.
SharkNinja Reports Third Quarter 2026 Results
Raises Fiscal Year 2026 Outlook Across Key Metrics on Strong Operational Performance
Performance Food Group Co
Performance Food Group Co
Performance Food Group Company Reports First-Quarter Fiscal 2027 Results
Trex Co Inc
News release
TREX COMPANY REPORTS Strong Third QUARTER 2026 RESULTS, DELIVERING BACK-TO-BACK RECORD QUARTERS
Solaredge Technologies, Inc.
SolarEdge Announces Third Quarter 2026 Financial Results
Revenue of $326.1 million, in line with the midpoint of guidance
Seres Therapeutics, Inc.
SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC)
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an…